CB-839 for Rectal Carcinoma
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
See full descriptionAbout the trial for Rectal Carcinoma
Treatment Groups
This trial involves 2 different treatments. CB-839 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether CB-839 will improve 2 primary outcomes and 1 secondary outcome in patients with Rectal Carcinoma. Measurement will happen over the course of At least 21 days of treatment.
Patient Q & A Section
What is rectal carcinoma?
The rectum is the most common site for colorectal carcinoma in the United States. Most people found to have [colo[rectal cancer](https://www.withpower.com/clinical-trials/rectal-cancer)](https://www.withpower.com/clinical-trials/colorectal-cancer) in the rectum are diagnosed at a relatively early stage. The most critical period leading to the development of cancer in this region is before age 40. A significant proportion of rectal carcinomas are detected incidentally at screening examinations for other chronic diseases or as a result of synchronous (in harmony) disease. Recent findings highlights the importance of screening for rectal cancer and the need to be aware of the epidemiology of the disease.
How many people get rectal carcinoma a year in the United States?
Almost [100,000 people] get rectal and colon carcinoma a year in the United States. About 90% of all rectal cancers occur in the right side. Most [90% or 99%] occur at or below the umbilicus. Rectal cancer has the [highest incidence] rate in all males.
What are common treatments for rectal carcinoma?
A variety of modalities are often used in the treatment of rectal cancer, including surgery, radiation, chemotherapy, and immunotherapy. However, the only certain treatment for rectal cancer that can reverse the initial problem is surgical resection. Even for those with a locally advanced rectal adenocarcinoma with no evidence of distant metastases, a surgical operation remains a first line treatment for local excision because of the risk of local recurrence.
Can rectal carcinoma be cured?
Despite radical surgery and an intensive adjuvant treatment approach, 20% of patients with cT3N0-3M0 stage II and III disease die of local recurrence or distant metastases.
What causes rectal carcinoma?
The colonic carcinoma was preceded by non-malignant colorectal lesions in about 15% cases (predominantly adenoma, or Tumor Microbiota Hypomineralization Syndrome-related), whereas the rectal carcinoma showed no pre-malignant lesion on a colonoscopic examination.
What are the signs of rectal carcinoma?
Rectal carcinoma (cancerous growth of the rectum) is usually diagnosed using a patient's history and physical examination. Other testing may also be ordered. Rectal bleeding is the most common symptom of rectal carcinoma. Other symptoms of rectal cancer include changes in bowel habits and a change in the shape or size of the bowel. When it is found by the person or family physician, the cancer may be spread.
What is the average age someone gets rectal carcinoma?
The age is lower than reported as it appears that women are dying from this cancer sooner than the average. There is a need for further consideration of gender specific cancers and how they may die earlier than would be expected, as they suffer from less effective cancer treatments as a result. Cancer 2015. © 2015 American Cancer Society.
What are the latest developments in cb-839 for therapeutic use?
Recently a new formulation of the CB-839 was developed to increase its activity against human squamous cell carcinoma in vitro. It is therefore hoped that a new clinical trial will be carried out with CB-839 using this formulation.
Have there been any new discoveries for treating rectal carcinoma?
The current practice for the treatment of rectal cancer in adults is still limited. There is an absence of data regarding the long-term outcomes of curative treatment.
What is the latest research for rectal carcinoma?
Recent studies have shown that patients with early stage rectal carcinoma can expect excellent 5-year survival with optimal local excision when treated by a team trained in rectal cancer surgery with adequate training in the operative laparoscopy technique. Patients with advanced rectal cancer can expect a 20-30% cure rate for those undergoing neoadjuvant therapy followed by radical operation involving a laparoscopic approach that is routinely performed by an experienced colorectal surgeon. Current adjuvant therapy options for early stage rectal carcinoma are neoadjuvant and surgical, typically followed by curative surgery and adjuvant chemotherapy.
Have there been other clinical trials involving cb-839?
There are no other known clinical trials that specifically test the ability of CB-839 to treat colon cancer. The most relevant trials on which we relied to design our trials are listed in the 'Related articles' section.
Does rectal carcinoma run in families?
Although patients with rectal carcinoma tend to have familial features in relatives, the familial risk is not related to a common genetic lesion. To determine whether an individual patient's cancer is associated with an inherited or environmental condition, one must first rule out known risk factors and assess the other family members who might have disease. Although an increased incidence of rectal carcinoma has been described in the literature in several family types, the precise mechanism is not known. A retrospective review of the medical records of 21 kindreds with rectal carcinoma showed that only 8 of the 21 patients (37.1%) had any evidence of disease in their relatives.